Loading
Dermatology and Skin Diseases · Journal article
Clinical and Experimental Dermatology · September 7, 2026
Reinforces what was already believed, rather than introducing something new.
This UK real-world registry study of 482 guselkumab-treated patients found consistent 36-month drug survival of 0.75 (95% CI, 0.71–0.79) overall, with no clinically significant variation by weight category, BMI category, or presence of comorbidities. The finding reinforces guselkumab's durability in routine practice across diverse patient phenotypes, though observational design and substantial missing baseline data limit causal inference.
Retrospective cohort study. 482 patients with moderate-to-severe psoriasis treated with guselkumab in the UK. Background context notes 89.1% of UK moderate-to-severe psoriasis patients are overweight or obese, and 53.2% have at least one comorbidity.. Intervention: Guselkumab treatment initiated in routine clinical practice. Compared with: Stratified comparison by weight category, BMI category, and presence versus absence of specific comorbidities. n = 482. United Kingdom.
Overall 36-month drug survival 0.75 (95% CI, 0.71–0.79) across 482 guselkumab-treated patients Stratified by weight: <80 kg 0.71 (95% CI, 0.59–0.86), 80–<90 kg 0.79 (95% CI, 0.71–0.87), 90–<100 kg 0.74 (95% CI, 0.68–0.82), ≥100 kg 0.74 (95% CI, 0.66–0.82) Drug survival by BMI: <30 kg/m² 0.78 (95% CI, 0.71–0.86) vs ≥30 kg/m² 0.73 (95% CI, 0.69–0.79)
No efficacy (e.g. PASI or IGA) or adverse event data stratified by weight or comorbidity; only discontinuation rates reported
Clinicians can be reassured that guselkumab maintains durable drug survival over 36 months in patients with obesity and common comorbidities in real-world practice, supporting its use across diverse patient phenotypes. However, the observational design and missing baseline data mean findings should be interpreted as supportive of continued use rather than as definitive evidence of equal efficacy across all subgroups.
Retrospective real-world registry analysis confirming sustained drug survival of guselkumab across weight, BMI, and comorbidity strata over 36 months, with consistent outcomes but limited by observational design and missing baseline data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians can be reassured that guselkumab maintains durable drug survival over 36 months in patients with obesity and common comorbidities in real-world practice, supporting its use across diverse patient phenotypes. However, the observational design and missing baseline data mean findings should be interpreted as supportive of continued use rather than as definitive evidence of equal efficacy across all subgroups.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
In the United Kingdom (UK), 89.1% of patients with moderate-to-severe psoriasis are overweight or obese, and 53.2% have at least one comorbidity. However, real-world data on biologic-treated patients with psoriasis and comorbidities remains limited. Objectives were to compare 36-month drug survival of guselkumab in patients across weight and body mass index (BMI) categories, and in those with or without specific comorbidities. This retrospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), collected from January 2018 to July 2024. Co-primary outcomes were overall drug survival, and drug survival stratified by weight and BMI categories, over 36 months, for guselkumab-treated patients. Secondary outcomes included 36-month drug survival among guselkumab-treated patients with and without specific comorbidities, including but not limited to, metabolic syndrome, hypertension, anxiety and/or depression. Kaplan-Meier methodology was used to estimate probabilities for time-to-treatment discontinuation across all patient groups analysed. Among the 482 participants included in this analysis who initiated guselkumab treatment, 36-month drug survival was generally high, with an overall drug survival rate of 0.75 (95% CI, 0.71-0.79). Stratified by weight, drug survival rates were 0.71 (95% CI, 0.59-0.86) for patients <80 kg, 0.79 (95% CI, 0.71-0.87) for those 80-<90 kg, 0.74 (95% CI, 0.68-0.82) for those 90-<100 kg, and 0.74 (95% CI, 0.66-0.82) for those ≥100 kg. Drug survival by BMI category was 0.78 (95% CI, 0.71-0.86) for patients <30 kg/m2 and 0.73 (95% CI, 0.69-0.79) for those ≥30 kg/m2. Across all comorbidities analysed, drug survival at 36 months remained ≥0.69, with no significant differences observed in patients with comorbidities compared to those without. In this UK real-world analysis, drug survival rates for guselkumab over 36 months were consistent across patients with psoriasis in different weight and BMI categories, and were not adversely affected by the presence of comorbidities. This analysis has limitations due to the high proportion of missing weight and BMI data at baseline. Nonetheless, these findings support guselkumab use as a durable treatment option in routine practice, for patients with obesity and other common comorbidities.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.